Implementing quality management strategies improves clinical quality as a voluntary medical male circumcision program in Namibia matures: a process analysis.
Adverse events
HIV prevention
Namibia
Quality
Voluntary Medical Male Circumcision (VMMC)
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
29 Sep 2023
29 Sep 2023
Historique:
received:
28
02
2023
accepted:
11
09
2023
medline:
5
10
2023
pubmed:
29
9
2023
entrez:
29
9
2023
Statut:
epublish
Résumé
Surgical voluntary medical male circumcision (VMMC) is a safe procedure; however, maintaining quality standards at scale, particularly during scale-up, is a challenge making ongoing quality management (QM) efforts essential. This study describes program quality measured by rates of adverse events (AEs) over four years of VMMC implementation in Namibia, compares AE rates over time, and discusses QM processes that contextualize AE trends and illustrate improvements in quality as the program matured. The International Training and Education Center for Health (I-TECH) assisted the Namibian Ministry of Health and Social Services (MoHSS) in expanding VMMC in three regions among boys and men over 10 years of age between January 2015 and September 2019. A comprehensive package of QM strategies was implemented by multi-disciplinary onsite teams with support from national and international technical advisors. Retrospective routine MoHSS data from the VMMC register, client forms, and monthly AE reports were collected during implementation in the three regions to assess the impact of QM interventions on AEs and to calculate the proportion of clients who experienced AEs over time. The proportion of clients who experienced an AE over time was compared using a Cochran-Armitage test for trend. Between January 2015 and September 2019, 40,336 clients underwent VMMC and 593 (1.5%) clients experienced a post-operative AE in the three supported regions. The AE rate was highest in the first quarter of clinical service delivery in each region (January-March 2015 in Oshana and Zambezi, October-December 2017 in //Kharas) but declined over the implementation period as the program matured. This observed trend between program maturity and declining AE rates over time was significant (p < 0.001) when compared using a Cochran-Armitage test for trend. As the I-TECH-supported VMMC program matured, QM measures were introduced and routinized, and clinical quality improved over time with the rate of AEs decreasing significantly over the implementation period. Applying systematic and continuous QM processes and approaches across the continuum of VMMC services and considering local context can contribute to increased clinical safety. QM measures that are established in more mature program sites can be quickly adopted to respond to quality issues in program expansion sites.
Sections du résumé
BACKGROUND
BACKGROUND
Surgical voluntary medical male circumcision (VMMC) is a safe procedure; however, maintaining quality standards at scale, particularly during scale-up, is a challenge making ongoing quality management (QM) efforts essential. This study describes program quality measured by rates of adverse events (AEs) over four years of VMMC implementation in Namibia, compares AE rates over time, and discusses QM processes that contextualize AE trends and illustrate improvements in quality as the program matured. The International Training and Education Center for Health (I-TECH) assisted the Namibian Ministry of Health and Social Services (MoHSS) in expanding VMMC in three regions among boys and men over 10 years of age between January 2015 and September 2019.
METHODS
METHODS
A comprehensive package of QM strategies was implemented by multi-disciplinary onsite teams with support from national and international technical advisors. Retrospective routine MoHSS data from the VMMC register, client forms, and monthly AE reports were collected during implementation in the three regions to assess the impact of QM interventions on AEs and to calculate the proportion of clients who experienced AEs over time. The proportion of clients who experienced an AE over time was compared using a Cochran-Armitage test for trend.
RESULTS
RESULTS
Between January 2015 and September 2019, 40,336 clients underwent VMMC and 593 (1.5%) clients experienced a post-operative AE in the three supported regions. The AE rate was highest in the first quarter of clinical service delivery in each region (January-March 2015 in Oshana and Zambezi, October-December 2017 in //Kharas) but declined over the implementation period as the program matured. This observed trend between program maturity and declining AE rates over time was significant (p < 0.001) when compared using a Cochran-Armitage test for trend.
CONCLUSIONS
CONCLUSIONS
As the I-TECH-supported VMMC program matured, QM measures were introduced and routinized, and clinical quality improved over time with the rate of AEs decreasing significantly over the implementation period. Applying systematic and continuous QM processes and approaches across the continuum of VMMC services and considering local context can contribute to increased clinical safety. QM measures that are established in more mature program sites can be quickly adopted to respond to quality issues in program expansion sites.
Identifiants
pubmed: 37773121
doi: 10.1186/s12913-023-10016-6
pii: 10.1186/s12913-023-10016-6
pmc: PMC10543846
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1044Subventions
Organisme : CDC HHS
ID : NU2GGH001430
Pays : United States
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Syst Rev. 2020 Apr 26;9(1):94
pubmed: 32336290
Curr HIV/AIDS Rep. 2022 Dec;19(6):508-515
pubmed: 36348185
PLoS One. 2014 Aug 21;9(8):e100008
pubmed: 25144194
PLoS One. 2017 Nov 7;12(11):e0185904
pubmed: 29112959
PLoS One. 2019 Oct 3;14(10):e0222180
pubmed: 31581192
PLoS One. 2015 Sep 25;10(9):e0138755
pubmed: 26405786
J Acquir Immune Defic Syndr. 2016 Jun 1;72 Suppl 1:S24-9
pubmed: 27331586
PLoS One. 2013 May 22;8(5):e63134
pubmed: 23717402
PLoS One. 2014 May 06;9(5):e84271
pubmed: 24802412
Glob Health Sci Pract. 2014 Jan 09;2(1):93-102
pubmed: 25276565
Bull World Health Organ. 2012 Oct 1;90(10):773-81
pubmed: 23109745
BMC Health Serv Res. 2016 Feb 17;16:61
pubmed: 26888178
Lancet. 2007 Feb 24;369(9562):657-66
pubmed: 17321311
PLoS One. 2015 Sep 14;10(9):e0137376
pubmed: 26367187
PLoS One. 2014 May 01;9(5):e95357
pubmed: 24788898
PLoS Med. 2005 Nov;2(11):e298
pubmed: 16231970
BMC Med Educ. 2017 Jun 2;17(1):98
pubmed: 28577536
PLoS One. 2021 Oct 20;16(10):e0258611
pubmed: 34669709
Digit Health. 2020 Apr 01;6:2055207620914772
pubmed: 32426151
Glob Health Action. 2018;11(1):1414997
pubmed: 29322867
Lancet. 2007 Feb 24;369(9562):643-56
pubmed: 17321310
J Acquir Immune Defic Syndr. 2015 May 1;69(1):e13-23
pubmed: 25942466
PLoS One. 2014 Jan 28;9(1):e86631
pubmed: 24489754
J Int AIDS Soc. 2014 Nov 17;17:19275
pubmed: 25406951
PLoS One. 2021 Aug 5;16(8):e0254850
pubmed: 34351933
PLoS One. 2014 May 06;9(5):e79524
pubmed: 24801073
J Int AIDS Soc. 2019 Jul;22(7):e25369
pubmed: 31368235